Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 catch-up vaccination study of Prevenar 20 in healthy children and adolescents
2025-523445-10-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Sep 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of Prevnar 20 in pneumococcal disease (2 arms), sponsored by Pfizer. Primary endpoints: Prespecified local reactions, Prespecified systemic events and 3 more. Planned start Sep 2026; status: authorised.
02
Drugs
Prevnar 20
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2025-523445-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523445-10-00.